Sabrina McIntyre

Sabrina McIntyre serves as a key procurement professional within the Office of the Assistant Secretary for Preparedness and Response at the U.S. Department of Health and Human Services, supporting the agency’s mission to accelerate the acquisition of medical countermeasures for public health emergencies. She manages complex research and development contracts focused on biodefense readiness, overseeing the procurement of advanced therapeutics, vaccines, and diagnostic platforms designed to mitigate biological threats. Her work is central to ensuring rapid deployment of innovative medical solutions through agile contracting mechanisms aligned with federal biodefense priorities. McIntyre maintains strategic relationships with specialized biotechnology firms including Cidara Therapeutics, Aquestive Therapeutics, Rafa Laboratories, and Osivax, all of which possess niche expertise in antiviral development, novel drug delivery systems, and pandemic-responsive vaccine platforms. Her contracting approach emphasizes partnerships with vendors possessing proven capabilities in GMP manufacturing, preclinical validation, and regulatory pathway acceleration, often leveraging Other Transaction Authorities and Broad Agency Announcements to expedite critical acquisitions. Her procurement portfolio is entirely non-set-aside, reflecting a mission-driven focus on technical capability over socioeconomic categorization. While small business participation is not formally prioritized through 8(a), HUBZone, or SDVOSB set-asides, her awards are determined strictly by technical merit, innovation readiness, and manufacturing scalability, aligning with the urgency of biodefense timelines. McIntyre’s primary focus is on NAICS 541714—Research and Development in Biotechnology—where she sources cutting-edge solutions in immunotherapeutics, mRNA platforms, antiviral small molecules, and rapid diagnostic assays. Her domain expertise lies in advancing next-generation medical countermeasures through early-stage R&D contracting, ensuring the nation’s preparedness infrastructure remains technologically agile and scientifically robust.